Compare MMA & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMA | MRKR |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 23.0M |
| IPO Year | 2023 | 2010 |
| Metric | MMA | MRKR |
|---|---|---|
| Price | $0.43 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 469.5K | 123.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.81 |
| 52 Week High | $2.88 | $4.07 |
| Indicator | MMA | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 33.82 | 40.79 |
| Support Level | $0.35 | $0.83 |
| Resistance Level | $1.45 | $1.44 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 19.50 | 5.65 |
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.